<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091490</url>
  </required_header>
  <id_info>
    <org_study_id>Nivo-DHAP-cHL-1</org_study_id>
    <nct_id>NCT04091490</nct_id>
  </id_info>
  <brief_title>Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)</brief_title>
  <acronym>Nivo-DHAP</acronym>
  <official_title>Dexamethasone, Cytarabine, Cisplatin and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP-cHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with
      relapsed/refractory Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Clinical Study of Safety and Efficacy of Treatment With Nivolumab and Dexamethasone,
      Cytarabine and Cisplatin (DHAP) in Patients With Relapsed/Refractory Hodgkin's Lymphoma
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) of Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Overall response rate (ORR), defined as proportion of patients with complete response (CR) or partial response (PR) in measurable lesions as defined by Lugano classification and duration of response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients with relapsed/refractory Hodgkin's lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab</description>
    <arm_group_label>Patients with relapsed/refractory Hodgkin's lymphoma</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Histologically confirmed Hodgkin's lymphoma

          -  Measurable disease (at least one lesion that can be accurately measured in at least
             two dimensions with spiral CT scan, min &gt; 15 mm in the longest diameter or &gt; 10 mm in
             the short axis)

          -  World Health Organization (WHO) performance status &lt; 2

          -  Relapsed or refractory to at least one prior treatment line

          -  No prior therapy with DHAP or Nivolumab

          -  No severe concurrent illness

        Exclusion Criteria:

          -  History of HIV

          -  Active Hepatitis B or Hepatitis C infection

          -  Uncontrolled infection (requiring intravenous treatment) at the time of enrollment

          -  Pregnancy or breastfeeding

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent

          -  Active or prior documented autoimmune disease requiring systemic treatment

          -  No receiving a live vaccine within 30 days prior to first dose of nivolumab

          -  History of non-infectious pneumonitis that required steroids

          -  Other malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladislav Sarzhevskiy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav Sarzhevskiy, PhD</last_name>
    <phone>+74956037217</phone>
    <email>vladsar100@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikita Mochkin, PhD</last_name>
    <phone>+74956037217</phone>
    <email>nickmed@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JM, Schmalz O, Tresckow BV, Engert A, Borchmann P. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma. 2016 May;57(5):1067-73. doi: 10.3109/10428194.2015.1083561. Epub 2015 Dec 23.</citation>
    <PMID>26693800</PMID>
  </reference>
  <reference>
    <citation>Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.</citation>
    <PMID>29584546</PMID>
  </reference>
  <results_reference>
    <citation>Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002 Oct;13(10):1628-35.</citation>
    <PMID>12377653</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

